| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Revvity, Inc.$105.63
+5.73 (+5.74%)
Market Cap
10.82 B
EPS
2.12
P/E Ratio
45.95 $
Value Trade
116.82 M
SEC Financials
Q2 2026Dilution Risk
Revenue
711.12 M
R&D Expenses
57.89 M
Operating CF
115.23 M
Total Assets
12.00 B
Total Liabilities
4.81 B
Equity
7.18 B
D/E Ratio
12,345
2.65 %
Week
1.93 %
1 Month
-2.04 %
3 Month
2.79 %
6 Month
-34.65 %
5 Year
2,826.79 %
All Time
Cash Data
Cash Position
860.32 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
1.68 M
52 Week Range
81.22 - 118.30
% held by Insiders
0.52 %
% held by Institutions
106.64 %
Enterprise Value
13.31 B
Total Shares
111.77 M
Short %
7.86 %
Float Shares
111.32 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RVTY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RVTY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVTY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVTY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RVTY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RVTY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RVTYRevvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
Revvity has introduced Signals AI, a new framework designed to accelerate scientific research and development. This innovative tool emphasizes privacy protection while enhancing the efficiency of R&D processes. The launch aims to provide researchers with advanced capabilities to drive scientific advancements.
Read more →RVTYRevvity Announces Financial Results for the First Quarter of 2026
Revvity has announced its financial results for the first quarter of 2026. The details of the financial performance and any significant changes or highlights were not provided in the article. Further insights into revenue, expenses, and future outlook are expected in subsequent communications.
Read more →RVTYRevvity Board Declares Quarterly Dividend
Revvity, Inc. has announced a quarterly dividend of $0.07 per share, payable on August 7, 2026, to shareholders of record by July 17, 2026. The company, which specializes in health science solutions, reported a revenue of $2.9 billion for 2025 and employs around 11,000 people. Revvity is recognized for its innovative contributions to healthcare.
Read more →RVTYRevvity to Hold Earnings Call on Tuesday, May 5, 2026
Revvity, Inc. will announce its first quarter 2026 financial results on May 5, 2026, before market opening. A conference call will follow at 7:30 a.m. ET, hosted by CEO Prahlad Singh and CFO Max Krakowiak. The company continues to demonstrate growth, reporting $2.9 billion in revenue for 2025.
Read more →RVTYRevvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
Revvity, Inc. has launched its Signals BioDesign, a cloud-native molecular cloning solution aimed at enhancing biologics research workflows. This platform simplifies complex cloning processes and promotes collaborative development for biotech and pharma R&D teams. It integrates with existing systems to streamline therapeutic construct design and management, addressing the needs of researchers in developing advanced therapies.
Read more →RVTYRevvity to Present at Upcoming Investor Conferences
Revvity, Inc. announced its participation in several upcoming investor conferences, including the Raymond James 47th Annual Institutional Investors Conference and the TD Cowen 46th Annual Health Care Conference. Key executives will provide updates on the company's strategic priorities during these events. Live audio webcasts will be available, along with replays for 30 days post-event.
Read more →RVTYRevvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
Revvity, Inc. has launched several new high-impact discovery platforms at SLAS2026, aimed at enhancing high-throughput drug discovery workflows. The new technologies include the Opera Phenix OptIQ™ screening system and the EnVision Nexus™ One multimode plate reader. These innovations are designed to integrate automation and AI to improve efficiency and data quality in discovery labs.
Read more →RVTYRevvity Announces Financial Results for the Fourth Quarter and Full Year of 2025
Revvity, Inc. reported strong financial results for Q4 and full year 2025, with revenue growth and improved adjusted earnings per share. The company anticipates continued growth in 2026, forecasting revenue between $2.96 and $2.99 billion. However, GAAP operating profit margins showed a slight decline, and overall GAAP earnings per share decreased compared to the previous year.
Read more →RVTYRevvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance
Revvity, Inc. will announce its Q4 and full year 2025 financial results on February 2, 2026, followed by a conference call. Preliminary results indicate strong financial performance, with a revenue of over $2.7 billion in 2024. The company will also present at the J.P. Morgan Healthcare Conference, showcasing its ongoing commitment to transparency and investor relations.
Read more →RVTYRevvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
Revvity has partnered with Eli Lilly to enhance access to Lilly's predictive models via the Revvity Signals platform. This collaboration aims to accelerate AI-enabled drug discovery by utilizing federated learning, allowing participating biotechs to apply Lilly's models while maintaining data privacy. The initiative is supported by joint funding to facilitate broader participation.
Read more →RVTYEXECUTION VERSION CUSIP Numbers: Deal: 76156EAA9 Revolver: 76156EAB7 CREDIT AGREEMENT Dated as of
Revvity Health Sciences, Inc. has entered into a credit agreement with several financial institutions, including JPMorgan Chase Bank and Goldman Sachs Bank USA. This agreement, dated January 7, 2025, involves commitments for loans and financial accommodations to the company and its subsidiaries. The details outlined in the agreement cover various financial terms, conditions, and administrative arrangements regarding the credit facilities provided by the participating lenders.
Read more →RVTYRevvity Announces Financial Results for the Fourth Quarter and Full Year of 2023 Fourth quarter revenue of $696 million; (6)% reported growth; (7)% organic growth; (3)% non-COVID organic growth Fourth quarter GAAP EPS of
Revvity, Inc. announced its financial results for the fourth quarter and full year of 2023, reporting a GAAP EPS of $0.64 and revenue of $696 million, both lower than the previous year's figures. The company indicated various decreases in operational income and profit margins amidst industry challenges. Despite these setbacks, Revvity initiated its revenue guidance for 2024, forecasting $2.79 to $2.85 billion. Overall, the company faced significant revenue and earnings declines year-over-year, reflecting ongoing pressures within the industry.
Read more →RVTYRevvity to Hold Earnings Call on Thursday
Revvity, Inc. announced that it will release its fourth quarter and full year 2023 financial results on February 1, 2024, and host a conference call at 8:00 a.m. ET on the same day. The preliminary expectation for Q4 revenue is at least $690 million, although this reflects a decline of approximately -7% year-over-year. Additionally, the company anticipates that its adjusted earnings per share for the full year 2023 will meet or exceed prior guidance, despite a projected -4% decline in non-COVID organic revenue. This financial information will be elaborated upon during the upcoming earnings call, which will be accessible through an audio webcast.
Read more →RVTYRevvity Announces Financial Results for the Third Quarter of 2023 Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing operations
Revvity, Inc. reported its financial results for Q3 2023, revealing a revenue of $671 million, a decline of 6% from the previous year. GAAP earnings per share decreased sharply to $0.08 from $0.67 year-over-year. The company updated its full year 2023 revenue guidance to between $2.72 billion and $2.74 billion, reflecting a cautious outlook amid challenging market conditions. Despite the downturn in financial metrics, Revvity's leadership expressed a focus on controllable factors to navigate the uncertain environment.
Read more →RVTYRevvity Announces Financial Results for the Second Quarter of 2023 Revenue of $709 million; (21)% reported growth; (20)% organic growth; 6% non-COVID organic growth GAAP EPS of $0.28; Adjusted EPS from continuing operati
Revvity, Inc. reported financial results for the second quarter of 2023, showing a revenue decline to $709 million, down 21% from the same period last year. The GAAP earnings per share significantly dropped to $0.28 compared to $1.42 a year ago. Adjusted earnings also fell, and operating income decreased sharply. Despite these setbacks, the company has updated its full-year guidance and expressed confidence in navigating the current market challenges.
Read more →RVTYRevvity Announces Financial Results for the First Quarter of 2023 Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operatio
Revvity, Inc. reported its financial results for Q1 2023, showing a total revenue of $675 million, which reflects a year-over-year decline. The company has experienced a notable drop in both GAAP and adjusted earnings per share, signaling challenges in maintaining profitability. Despite these issues, Revvity has initiated a $600 million share repurchase program and provided optimistic revenue projections for the full year. The transition to the new ticker 'RVTY' is set to occur on May 16, 2023, aligning with the company's rebranding efforts.
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022 Fourth quarter revenue from continuing operations of $741 million; (28)% reported growth; (23)% organic growth; 8% non-COVID organic gr
PerkinElmer reported its financial results for the fourth quarter of 2022, showing a drop in GAAP earnings per share and revenue compared to the previous year. Total fourth quarter revenue from continuing operations was $741 million, representing a decline from $1,028 million year-over-year. Despite this downturn in financials, the company announced guidance for 2023, projecting a revenue of $2.94 billion while also emphasizing a shift towards separating into two standalone companies focused on future growth. Adjusted earnings per share for the full year 2022 also saw a decrease from $11.36 in 2021 to $7.95.
Read more →RVTYPerkinElmer To Hold Earnings Call on Tuesday
PerkinElmer Inc. will release its fourth quarter and full year 2022 financial results on February 14, 2023. A conference call led by the CEO and CFO will follow to discuss the results. The company has updated its fourth quarter outlook, now anticipating results that meet or exceed prior guidance. This announcement highlights the company's commitment to innovation and addressing critical challenges across various sectors.
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2022 Third quarter revenue of $712 million; (17)% reported growth Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth Third q
PerkinElmer Announces Financial Results for the Third Quarter of 2022 Third quarter revenue of $712 million; (17)% reported growth Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth Third quarter GAAP EPS from continuing operations of $0.55; pro
Read more →RVTYPerkinElmer to Hold Earnings Call on Tuesday
PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook WALTHAM, Mass.--(BUSINESS WIRE)--October 17, 2022--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it will release its full
Read more →RVTYEMPLOYMENT AGREEMENT This Employment Agreement (the Agreement ) effective as of
EMPLOYMENT AGREEMENT This Employment Agreement (the Agreement ) effective as of September 6, 2022 between PerkinElmer, Inc., a Massachusetts corporation (hereinafter called the Company ), and Maxwell Krakowiak (hereinafter referred to as the Employee ). Company wishes to emplo
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2022 Signs agreement with the intention to divest Applied, Food, and Enterprise Services businesses Second quarter revenue of $1.23 billion; 0% reported g
PerkinElmer Announces Financial Results for the Second Quarter of 2022 Signs agreement with the intention to divest Applied, Food, and Enterprise Services businesses Second quarter revenue of $1.23 billion; 0% reported growth, 8% non-COVID organic growth Second quarter GAAP EP
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2022 First quarter revenue of $1.26 billion First quarter GAAP EPS from continuing operations of $1.40; Adjusted EPS of $2.41 Initiates Second Quarter and
PerkinElmer Announces Financial Results for the First Quarter of 2022 First quarter revenue of $1.26 billion First quarter GAAP EPS from continuing operations of $1.40; Adjusted EPS of $2.41 Initiates Second Quarter and Raises Full Year Guidance WALTHAM, Mass.--(BUSINESS WIRE
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2021 4Q Revenue of $1.36 billion; 1% reported growth; -9% organic growth 4Q GAAP EPS from continuing operations of $1.41; Adjusted EPS of $2
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2021 4Q Revenue of $1.36 billion; 1% reported growth; -9% organic growth 4Q GAAP EPS from continuing operations of $1.41; Adjusted EPS of $2.56 Initiates First Quarter and Full Year 2022 Guidance
Read more →RVTYPerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1, 2022 Fourth quarter 2021 revenue and earnings per share to exceed prior guidance Non-COVID organic growth in fourth quarter 2021 of approximately 10% Fourth quarter 2021 COVID product and
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2021 Revenue of $1.17 billion; 21% reported growth; 12% organic growth GAAP EPS from continuing operations of $1.11; Adjusted EPS of $2.31 Initiates Fourth
PerkinElmer Announces Financial Results for the Third Quarter of 2021 Revenue of $1.17 billion; 21% reported growth; 12% organic growth GAAP EPS from continuing operations of $1.11; Adjusted EPS of $2.31 Initiates Fourth Quarter Guidance and Raises Full Year Revenue and Earnin
Read more →RVTYEXECUTION VERSION Published CUSIP Numbers: Deal: 71404HAL9 Revolver: 71404HAM7 CREDIT AGREEMENT Dated as of
Dated as of August 24, 2021 PERKINELMER HEALTH SCIENCES, INC., PERKINELMER LIFE SCIENCES INTERNATIONAL HOLDINGS, PERKINELMER GLOBAL HOLDINGS S. R.L, PERKINELMER HEALTH SCIENCES B.V. CERTAIN OTHER SUBSIDIARIES OF BANK OF AMERICA, N.A., Administrative Agent, the Swing Line L
Read more →RVTYEXECUTION VERSION TERM LOAN CREDIT AGREEMENT Dated as of
LOAN CREDIT AGREEMENT Dated as of August 11, 2021 as the Administrative Agent, GOLDMAN SACHS BANK USA JPMORGAN CHASE BANK, N.A. WELLS FARGO BANK, NATIONAL as Co-Documentation Agents, The Other Lenders Party GOLDMAN SACHS BANK USA, BANK OF AMERICA, N.A., FARGO BANK, NATI
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2021 Revenue of $1.228 billion; 51% reported growth; 41% organic growth GAAP EPS from continuing operations of $2.19; Adjusted EPS of $2.83 Initiates Thir
PerkinElmer Announces Financial Results for the Second Quarter of 2021 Revenue of $1.228 billion; 51% reported growth; 41% organic growth GAAP EPS from continuing operations of $2.19; Adjusted EPS of $2.83 Initiates Third Quarter and Raises Full-Year Revenue and Earnings Guida
Read more →RVTYPerkinElmer to Acquire Antibody and Reagent Leader BioLegend Transformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine Leader in antibody developm
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend Transformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine WALTHAM, Mass. July 26, 2021 PerkinElmer, Inc. (NYSE: PKI) ( PerkinElmer ) today ann
Read more →RVTYPerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday
PerkinElmer Provides Update on Second Quarter Performance and Schedules Earnings Call for Wednesday, July 28, 2021 Company anticipates 2Q21 revenue and earnings to be above previously communicated guidance WALTHAM, Mass.--(BUSINESS WIRE)--June 24, 2021--PerkinElmer, Inc. (NYSE:
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2021 Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Seco
PerkinElmer Announces Financial Results for the First Quarter of 2021 Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings Guid
Read more →RVTYPerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday
PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021 Company also announces appointment of Steve Willoughby as vice president, investor relations WALTHAM, Mass.--(BUSINESS WIRE)--April 13, 2021--PerkinElmer, Inc. (NYSE: PKI), a global l
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020 4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020 4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of $3.96 Initiates First Quarter and Full Year 2021 Guidance
Read more →RVTYJ.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer
Executive Officer January 11, 2021 1Exhibit 99.1 J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer January 11, 2021 1 SAFE HARBOR This presentation contains forward-looking statements which are statements relating to future events. These statements include
Read more →RVTYPerkinElmer to Acquire Oxford Immunotec Global PLC PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash Transaction expected to be completed in the first half of 2021 WALTHAM, Mass. and LONDON
PerkinElmer to Acquire Oxford Immunotec WALTHAM, Mass. and LONDON, January 7, 2021 PerkinElmer, Inc. (NYSE: PKI) ( PerkinElmer ) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ( Oxford Immunotec or the Company ) are pleased to announce they have reached an agreement on terms un
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2020 Revenue of $964.0 million; 36% reported growth; 34% organic growth GAAP EPS from continuing operations of $1.57; Adjusted EPS of $2.09 WALTHAM, Mass.-
PerkinElmer Announces Financial Results for the Third Quarter of 2020 Revenue of $964.0 million; 36% reported growth; 34% organic growth GAAP EPS from continuing operations of $1.57; Adjusted EPS of $2.09 WALTHAM, Mass.--(BUSINESS WIRE)--October 28, 2020--PerkinElmer, Inc. (NY
Read more →RVTYPerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday
PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020 WALTHAM, Mass.--(BUSINESS WIRE)--October 12, 2020--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates re
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2020 Revenue of $811.7 million; 12% reported growth; 13% organic growth GAAP EPS from continuing operations of $1.23; Adjusted EPS of $1.57 WALTHAM, Mass.
PerkinElmer Announces Financial Results for the Second Quarter of 2020 Revenue of $811.7 million; 12% reported growth; 13% organic growth GAAP EPS from continuing operations of $1.23; Adjusted EPS of $1.57 WALTHAM, Mass.--(BUSINESS WIRE)--July 28, 2020--PerkinElmer, Inc. (NYSE
Read more →RVTYPerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday
PerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday, July 28, 2020 WALTHAM, Mass.--(BUSINESS WIRE)--July 13, 2020--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2020 Revenue of $652.4 million; 1% reported growth; (1)% organic growth GAAP EPS from continuing operations of $0.30; Adjusted EPS of $0.67 Withdrawing pre
PerkinElmer Announces Financial Results for the First Quarter of 2020 Revenue of $652.4 million; 1% reported growth; (1)% organic growth GAAP EPS from continuing operations of $0.30; Adjusted EPS of $0.67 Withdrawing previously disseminated FY20 guidance due to COVID-related u
Read more →RVTYTime-Vested RSU (Single Trigger) PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a
Time-Vested RSU (Single Trigger) Restricted Stock Unit Agreement 2019 Stock Incentive Plan Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the Company ), and the Participant named below. Name of Partici
Read more →RVTYPerkinElmer First Quarter 2020 Financial Performance Update
PerkinElmer First Quarter 2020 Financial Performance Update WALTHAM, Mass. March 9, 2020 PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it expects first quarter 2020 revenue and earnings per share, both on a GA
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2019 4Q Revenue of $805.5 million; 6% reported growth; 5% organic growth 4Q GAAP EPS from continuing operations of $0.58; Adjusted EPS of $1.35
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2019 4Q Revenue of $805.5 million; 6% reported growth; 5% organic growth 4Q GAAP EPS from continuing operations of $0.58; Adjusted EPS of $1.35 4Q GAAP operating income margin of 17.2%; Adjusted opera
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2019 Revenue of $706.9 million; 5% Reported growth; Organic growth of 5% GAAP EPS from continuing operations of $0.53; Adjusted EPS of $1.06 GAAP operating
PerkinElmer Announces Financial Results for the Third Quarter of 2019 Revenue of $706.9 million; 5% Reported growth; Organic growth of 5% GAAP EPS from continuing operations of $0.53; Adjusted EPS of $1.06 GAAP operating income margin from continuing operations of 11.1%; Adjus
Read more →RVTYAMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the Agreement ) made this 30 th day of December, 2019 (the Effective Date ) between PerkinElmer, Inc., a Massachusetts corporation
AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the Agreement ) made this 30th day of December, 2019 (the Effective Date ) between PerkinElmer, Inc., a Massachusetts corporation (hereinafter called the Company ), and Prahlad R. Singh (h
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2019 Revenue of $722.5 million; 3% Reported growth; Organic growth of 5% GAAP EPS from continuing operations of $0.62; Adjusted EPS of $1.00 GAAP operatin
PerkinElmer Announces Financial Results for the Second Quarter of 2019 Revenue of $722.5 million; 3% Reported growth; Organic growth of 5% GAAP EPS from continuing operations of $0.62; Adjusted EPS of $1.00 GAAP operating income margin from continuing operations of 12.7%; Adju
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2019 Revenue of $648.7 million; 1% Reported growth; Organic growth of 5% GAAP EPS from continuing operations of $0.32; Adjusted EPS of $0.69 Acquisition of
Announces Financial Results for the First Quarter of 2019 of $648.7 million; 1% Reported growth; Organic growth of 5% EPS from continuing operations of $0.32; Adjusted EPS of $0.69 of Cisbio Bioassays, a leading custom assay service provider, bolsters position in life science
Read more →RVTYRSU - Board PERKINELMER, INC. Restricted Stock Unit Agreement 2019 Stock Incentive Plan This Restricted Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corpora
Restricted Stock Unit Agreement 2019 Stock Incentive Plan Stock Unit Agreement is made as of the Grant Date set forth below between PerkinElmer, Inc., a Massachusetts corporation (the Company ), and the Participant named below. Name of Participant (the Participant ): Grant D
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2018 Fourth Quarter 2018 GAAP revenue growth of 18% to $756.3 million; Core organic revenue growth of 7% Fourth Quarter 2018 GAAP earnings per
Announces Financial Results for the Fourth Quarter and Full Year 2018 Quarter 2018 GAAP revenue growth of 18% to $756.3 million; Core organic revenue growth of 7% Quarter 2018 GAAP earnings per share from continuing operations of $0.64; Adjusted earnings per share of $1.18 C
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2018 GAAP revenue growth of 22% to $674.3 million; Core organic revenue growth of 7% GAAP earnings per share from continuing operations of $0.68; Adjusted
Announces Financial Results for the Third Quarter of 2018 revenue growth of 22% to $674.3 million; Core organic revenue growth earnings per share from continuing operations of $0.68; Adjusted earnings per share of $0.90, an increase of 23% WALTHAM, Mass.--(BUSINESS WIRE)--Oct
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2018 GAAP revenue growth of 29% to $703.4 million; Core Organic revenue growth of 10% GAAP earnings per share from continuing operations of $0.58; Adjuste
Announces Financial Results for the Second Quarter of 2018 revenue growth of 29% to $703.4 million; Core Organic revenue growth earnings per share from continuing operations of $0.58; Adjusted earnings per share of $0.91, an increase of 36% operating income margin of 12.5%; A
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2018 First Quarter 2018 GAAP revenue growth of 25% to $644 million; 6% organic revenue growth First Quarter 2018 GAAP earnings per share from continuing op
Announces Financial Results for the First Quarter of 2018 Quarter 2018 GAAP revenue growth of 25% to $644 million; 6% organic Quarter 2018 GAAP earnings per share from continuing operations of $0.23; Adjusted earnings per share of $0.63, an increase of 15% WALTHAM, Mass.--(BU
Read more →RVTYEMPLOYMENT AGREEMENT This Employment Agreement (the Agreement ) made this 10th day of April, 2018 between PerkinElmer, Inc., a Massachusetts corporation (hereinafter called the Company ), and James Mock (hereinafter refe
EMPLOYMENT AGREEMENT This Employment Agreement (the Agreement ) made this 10th day of April, 2018 between PerkinElmer, Inc., a Massachusetts corporation (hereinafter called the Company ), and James Mock (hereinafter referred to as the Employee ). Company wishes to employ the E
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2017 Fourth Quarter 2017 GAAP revenue growth of 13% to $642 million; 6% organic revenue growth excluding EUROIMMUN Fourth Quarter 2017 GAAP los
Announces Financial Results for the Fourth Quarter and Full Year 2017 Quarter 2017 GAAP revenue growth of 13% to $642 million; 6% organic revenue growth excluding EUROIMMUN Quarter 2017 GAAP losses per share from continuing operations of $0.35; Adjusted earnings per share of
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2017 GAAP revenue growth of 8% to $554 million; 5% organic revenue growth GAAP earnings per share from continuing operations of $0.87; Adjusted earnings pe
Announces Financial Results for the Third Quarter of 2017 revenue growth of 8% to $554 million; 5% organic revenue growth earnings per share from continuing operations of $0.87; Adjusted earnings per share of $0.73, an increase of 14% operating margin of 14.4%; Adjusted opera
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2017 GAAP and adjusted revenues of $547 million GAAP earnings per share from continuing operations of $0.57; Adjusted earnings per share of $0.67 GAAP ope
PerkinElmer Announces Financial Results for the Second Quarter of 2017 GAAP and adjusted revenues of $547 million GAAP earnings per share from continuing operations of $0.57; Adjusted earnings per share of $0.67 GAAP operating margins expand by 150 basis points; Adjusted opera
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2017 GAAP revenue of $514 million, an increase of 3%; Organic revenue increased 4% GAAP earnings per share from continuing operations of $0.33; Adjusted ea
Announces Financial Results for the First Quarter of 2017 revenue of $514 million, an increase of 3%; Organic revenue increased earnings per share from continuing operations of $0.33; Adjusted earnings per share of $0.55 full year revenue and earnings per share guidance WALT
Read more →RVTYPerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016 The Company's Medical Imaging business has been moved into discontinued operations due to the pending sale Announces new reporting segments of
Announces Financial Results Fourth Quarter and Full Year 2016 Company's Medical Imaging business has been moved into discontinued operations due to the pending sale new reporting segments of Discovery & Analytical Solutions (DAS) and WALTHAM, Mass.--(BUSINESS WIRE)--February
Read more →RVTYPerkinElmer, Inc. Restricted Stock Agreement under 2009 Incentive Plan This AGREEMENT made as of the day of ( month ) 20XX, between PerkinElmer, Inc., a Massachusetts corporation (the Company ), and (the Participant ). F
Stock Agreement under 2009 Incentive Plan This AGREEMENT made as of the day of (month) 20XX, between PerkinElmer, Inc., a Massachusetts corporation (the Company ), and (the Participant ). For valuable consideration, receipt of which is acknowledged, the parties hereto agree as
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2016 GAAP Revenue of $548 million versus $563 million in the comparable prior period GAAP earnings per share from continuing operations of $0.52; Adjusted
Announces Financial Results for the Third Quarter of 2016 Revenue of $548 million versus $563 million in the comparable prior earnings per share from continuing operations of $0.52; Adjusted earnings per share of $0.68 operating profit margin of 14.8%; Adjusted operating prof
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2016 Revenue of $573 million vs. guidance range of $570 million to $575 million GAAP earnings per share from continuing operations of $0.56; Adjusted earn
Announces Financial Results for the Second Quarter of 2016 of $573 million vs. guidance range of $570 million to $575 million earnings per share from continuing operations of $0.56; Adjusted earnings per share of $0.67 operating profit margin of 12.4%; Adjusted operating prof
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2016 GAAP revenue of $539 million; Organic revenue growth of 4% GAAP earnings per share from continuing operations of $0.43; Adjusted earnings per share gr
Announces Financial Results for the First Quarter of 2016 revenue of $539 million; Organic revenue growth of 4% earnings per share from continuing operations of $0.43; Adjusted earnings per share growth of 12% to $0.56 adjusted operating profit margin by 100 basis points WAL
Read more →RVTYPerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2015 Fourth quarter 2015 GAAP revenue of $608.1 million; Constant currency adjusted revenue growth of 5%; Organic revenue growth of 3% Fourth quart
Announces Financial Results for Fourth Quarter and Full Year 2015 quarter 2015 GAAP revenue of $608.1 million; Constant currency adjusted revenue growth of 5%; Organic revenue growth of 3% quarter 2015 GAAP earnings per share from continuing operations of $0.61; Adjusted earn
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2015 GAAP revenue of $563 million; Constant currency adjusted revenue growth 10%; Organic revenue growth 6% GAAP earnings per share from continuing operati
Announces Financial Results for the Third Quarter of 2015 revenue of $563 million; Constant currency adjusted revenue growth 10%; Organic revenue growth 6% earnings per share from continuing operations of $0.48; Adjusted earnings per share of $0.60 representing 16% constant c
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2015 GAAP revenue of $564 million; Constant currency adjusted revenue growth 8%; Organic revenue growth 4% GAAP earnings per share from continuing operati
Announces Financial Results for the Second Quarter of 2015 revenue of $564 million; Constant currency adjusted revenue growth 8%; Organic revenue growth 4% earnings per share from continuing operations of $0.43; Adjusted earnings per share of $0.60 representing 12% constant c
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2015 GAAP revenue of $527 million; Constant currency adjusted revenue growth 5%; Organic revenue growth 3% GAAP earnings per share from continuing operatio
Announces Financial Results for the First Quarter of 2015 revenue of $527 million; Constant currency adjusted revenue growth 5%; Organic revenue growth 3% earnings per share from continuing operations of $0.36; Adjusted earnings per share of $0.50 representing 19% constant cu
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter of 2014 Revenue growth of 3%; Organic revenue growth 5% GAAP earnings per share from continuing operations of $0.28; Adjusted earnings per share increase of
Announces Financial Results for the Fourth Quarter of 2014 growth of 3%; Organic revenue growth 5% earnings per share from continuing operations of $0.28; Adjusted earnings per share increase of 15% to $0.85 adjusted operating profit margin by 200 basis points cash flow from
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2014 Revenue growth of 4%; organic and adjusted revenue growth of 4% GAAP earnings per share from continuing operations of $0.38; adjusted earnings per sha
Announces Financial Results for the Third Quarter of 2014 growth of 4%; organic and adjusted revenue growth of 4% earnings per share from continuing operations of $0.38; adjusted earnings per share increased 14% to $0.57 adjusted operating profit margin by 110 basis points c
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2014 Revenue growth of 3%; Adjusted and organic revenue growth of 2% GAAP earnings per share from continuing operations of $0.46; Adjusted earnings per sh
Announces Financial Results for the Second Quarter of 2014 growth of 3%; Adjusted and organic revenue growth of 2% earnings per share from continuing operations of $0.46; Adjusted earnings per share increased 16% to $0.59 adjusted operating profit margin by 110 basis points
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2014 Reported and Organic revenue growth of 5% GAAP earnings per share from continuing operations of $0.30; Adjusted earnings per share of $0.46, an increa
Announces Financial Results for the First Quarter of 2014 and Organic revenue growth of 5% earnings per share from continuing operations of $0.30; Adjusted earnings per share of $0.46, an increase of 28% cash flow from continuing operations of $68 million WALTHAM, Mass.--(BU
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter of 2013 Revenue growth of 4%; Organic revenue growth of 3% GAAP earnings per share from continuing operations of $0.58; Adjusted earnings per share of $0.73
Announces Financial Results for the Fourth Quarter of 2013 growth of 4%; Organic revenue growth of 3% earnings per share from continuing operations of $0.58; Adjusted earnings per share of $0.73 income from continuing operations was $85 million; Adjusted operating profit mar
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2013 Revenue growth of 3%; Organic and adjusted revenue growth of 2% GAAP earnings per share from continuing operations of $0.36; Adjusted earnings per sha
Announces Financial Results for the Third Quarter of 2013 growth of 3%; Organic and adjusted revenue growth of 2% earnings per share from continuing operations of $0.36; Adjusted earnings per share of $0.49 FY2013 GAAP earnings per share guidance from continuing operations to
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2013 Revenue growth of 4%; Adjusted and organic revenue growth of 3% GAAP earnings per share from continuing operations of $0.24; Adjusted earnings per sh
Announces Financial Results for the Second Quarter of 2013 growth of 4%; Adjusted and organic revenue growth of 3% earnings per share from continuing operations of $0.24; Adjusted earnings per share of $0.51 GAAP earnings per share guidance to $1.40 to $1.47; Updates adjusted
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2013 Revenue decline of 1%; Organic revenue declined 1% GAAP earnings per share from continuing operations of $0.28; Adjusted earnings per share of $0.36 R
Announces Financial Results for the First Quarter of 2013 decline of 1%; Organic revenue declined 1% earnings per share from continuing operations of $0.28; Adjusted earnings per share of $0.36 GAAP earnings per share guidance to $1.30 to $1.40; Adjusted earnings per share g
Read more →RVTYPerkinElmer Announces Financial Results for the Fourth Quarter of 2012 Revenue growth of 6%; Organic revenue growth of 3% GAAP loss per share from continuing operations of $0.14; Adjusted earnings per share of $0.65 Full
Announces Financial Results for the Fourth Quarter of 2012 growth of 6%; Organic revenue growth of 3% loss per share from continuing operations of $0.14; Adjusted earnings year revenue growth of 10%; Organic revenue growth of 5%; Adjusted operating profit margin increase of 1
Read more →RVTYPerkinElmer Announces Financial Results for the Third Quarter of 2012 Revenue growth of 13%; Organic revenue growth of 6% GAAP earnings per share from continuing operations of $0.25; Adjusted earnings per share of $0.45
Announces Financial Results for the Third Quarter of 2012 growth of 13%; Organic revenue growth of 6% earnings per share from continuing operations of $0.25; Adjusted earnings per share of $0.45 FY 2012 GAAP earnings per share from continuing operations guidance to $1.22 to
Read more →RVTYPerkinElmer Announces Financial Results for the Second Quarter of 2012 Revenue growth of 9%; Organic revenue growth of 5% GAAP earnings per share from continuing operations of $0.29; Adjusted earnings per share of $0.53,
Announces Financial Results for the Second Quarter of 2012 growth of 9%; Organic revenue growth of 5% earnings per share from continuing operations of $0.29; Adjusted earnings per share of $0.53, up 23% profit margin from continuing operations of 10%; Adjusted operating prof
Read more →RVTYPerkinElmer Announces Financial Results for the First Quarter of 2012 Revenue of $511 million, reported revenue growth of 14% and organic revenue growth of 6% Operating income from continuing operations of $36 million; A
Announces Financial Results for the First Quarter of 2012 of $511 million, reported revenue growth of 14% and organic revenue income from continuing operations of $36 million; Adjusted operating income of $79 million, up 160 basis points as a percentage of adjusted earnings p
Read more →Competitive Position
How RVTY ranks across every disease it competes inCompetitive Position is a premium feature
See how RVTY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial